Acute Ischemic Stroke and Heart Failure: Stroke Risk Factors Associated with Exclusion from Thrombolytic Therapy

Carolyn Breauna Sanders1, Krista Knisely1, Chase Rathfoot1

  • 1368074School of Medicine Greenville, University of South Carolina, Greenville, SC, USA.

Insights

Older patients with heart failure experiencing acute ischemic stroke are less likely to receive recombinant tissue plasminogen activator (rtPA) therapy due to factors like coronary artery disease and elevated INR. Developing targeted strategies can improve rtPA eligibility for these patients.

Area of Science:

  • Neurology
  • Cardiology
  • Stroke Medicine

Background:

  • Acute ischemic stroke (AIS) patients with congestive heart failure (HF) often have risk factors complicating treatment.
  • Recombinant tissue plasminogen activator (rtPA) is a critical treatment for AIS, but its use in AIS-HF patients is less understood.
  • Identifying specific risk factors for rtPA exclusion in AIS-HF patients is crucial for optimizing care.

Purpose of the Study:

  • To identify the risk factors associated with the exclusion of AIS patients with HF from rtPA therapy.
  • To analyze the characteristics of AIS-HF patients who receive or do not receive rtPA.

Main Methods:

  • Retrospective analysis of 5469 AIS patients (590 with HF) from a regional stroke registry (2010-2016).
  • Logistic regression analysis was used to determine risk factors for rtPA exclusion in AIS-HF patients.
  • Evaluation of baseline risk factors including age, coronary artery disease, and INR.

Main Results:

  • Older age (OR=0.982), coronary artery disease (OR=0.618), and elevated INR (OR=0.326) were associated with rtPA exclusion in AIS-HF patients.
  • AIS-HF patients receiving rtPA were more likely to show improved ambulatory status (OR=1.69).
  • The model demonstrated strong discriminating power with an AUROC of 0.668.

Conclusions:

  • Specific risk factors, including advanced age, coronary artery disease, and elevated INR, are linked to rtPA exclusion in AIS-HF patients.
  • These findings highlight the need for tailored management strategies to enhance rtPA eligibility for older HF patients.
  • Developing targeted interventions can improve treatment outcomes for AIS-HF patients.

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
43
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.4K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
27
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
849
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25